Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

<p>Supplementary Table S1. Patient Characteristics.</p>

Bewaard in:
Bibliografische gegevens
Hoofdauteur: Qingsheng Xu (17078830) (author)
Andere auteurs: Kaiyuan Huang (17078833) (author), Xiangqi Meng (17078836) (author), Yuxiang Weng (17078839) (author), Luyuan Zhang (17078842) (author), Linghao Bu (17078845) (author), Xiujue Zheng (17078848) (author), Jinquan Cai (17078851) (author), Renya Zhan (17078854) (author), Qun Chen (17078857) (author)
Gepubliceerd in: 2025
Onderwerpen:
Cancer
Clinical Research and Trials
Clinical Trial Results
Phase II clinical trials
CNS Cancers
Gliomas, Glioblastomas
Precision Medicine
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items